Introduction {#tca12943-sec-0005}
============

Small cell lung cancer (SCLC) is a deadly malignancy that affects nearly 25 000 people in the United States each year. SCLC comprises approximately 15% of new lung cancer diagnoses.[1](#tca12943-bib-0001){ref-type="ref"} The US Preventative Services Task Force recommends computed tomography (CT) lung cancer screening for long‐term smokers, which will likely increase the incidence of early‐stage lung cancer diagnosis.[2](#tca12943-bib-0002){ref-type="ref"} Stage T1‐2N0M0 disease accounts for nearly 5% of patients diagnosed with SCLC and is amenable to surgical resection.[3](#tca12943-bib-0003){ref-type="ref"}

The standard treatment for SCLC is chemotherapy, either alone or in combination with concurrent radiotherapy.[4](#tca12943-bib-0004){ref-type="ref"} Although SCLC is highly sensitive to chemotherapy and radiotherapy, the rate of local recurrence is reported to be as high as 50% in limited‐stage disease.[5](#tca12943-bib-0005){ref-type="ref"}, [6](#tca12943-bib-0006){ref-type="ref"} There is renewed interest in using surgical resection to obtain better local control of early‐stage SCLC. Previous studies have investigated the combination of surgery with adjuvant chemotherapy and radiotherapy to improve local recurrence rates.[7](#tca12943-bib-0007){ref-type="ref"}, [8](#tca12943-bib-0008){ref-type="ref"}

The National Comprehensive Cancer Network (NCCN) guidelines recommend surgery only for stage I SCLC disease and specify that lobectomy is the preferred resection procedure.[9](#tca12943-bib-0009){ref-type="ref"}, [10](#tca12943-bib-0010){ref-type="ref"} In contrast, according to a study from the National Cancer Data Base, approximately 30% of patients with stage I SCLC underwent sublobar resection.[11](#tca12943-bib-0011){ref-type="ref"} No published prospective studies have compared the equivalency of lobectomy and sublobar resection. Herein, we investigate the survival rates of patients with pathological stage T1‐2N0M0 SCLC who underwent lobectomy or sublobar resection, based on data from the Surveillance, Epidemiologic, and End Results (SEER) database.

Methods {#tca12943-sec-0006}
=======

This retrospective study used data from SEER, which covers approximately 28% of the United States population.[12](#tca12943-bib-0012){ref-type="ref"} Relevant details on SCLC were retrieved with the use of SEER\*Stat version 8.3.4 software. Patients diagnosed with pathological stage T1‐2N0M0 SCLC from 1998 to 2013 were identified (Fig [S1](#tca12943-supitem-0001){ref-type="supplementary-material"}). Staging was performed using the 8th edition Union for International Cancer Control Tumor Node Metastasis (TNM) Classification. Tumor histology was coded according to the International Classification of Diseases for Oncology, 3rd edition. The codes 8041/3--8045/3 were used, which correspond to small cell carcinoma (not otherwise specified \[NOS\]), oat cell carcinoma (Oat), small cell carcinoma (fusiform cell), small cell carcinoma (intermediate cell), and combined small cell carcinoma, respectively.

The data are presented as medians (range) and percentages. Baseline characteristics were compared by surgical type using the independent sample *t*‐test for continuous variables and the chi‐square test for categorical variables. Overall survival (OS) and lung cancer‐specific survival (LCSS) were estimated using the Kaplan--Meier method (log‐rank test). Survival data was obtained from the SEER database. When analyzing LCSS, deaths from other causes were censored at the date of death.

We performed propensity score matching (PSM) analysis to compare survival among the lobectomy and sublobar cohorts. First, we created a propensity score for the sublobar cohort using logistic regression based on potential confounding variables, including age, gender, tumor size, and radiotherapy. A balanced cohort was created using a one‐to‐one nearest‐neighbor matching algorithm.[13](#tca12943-bib-0013){ref-type="ref"} Univariate and multivariate analyses were conducted by Cox regression. A Cox multivariate model was constructed including the covariates of age, gender, and surgical type, which were statistically significant in univariate analysis. In consideration of clinical factors and previous studies, tumor size and radiotherapy were also included in the Cox model.

All statistical analyses were performed using SPSS version 20.0 (IBM Corp., Armonk, NY, USA) or GraphPad Prism version 5.0 (La Jolla, CA, USA). PSM analysis was performed using R 3.4.2 (R Development Core Team, R Foundation for Statistical Computing, Vienna, Austria), including "MatchIt" packages. Results were considered statistically significant at *P* \< 0.05.

Results {#tca12943-sec-0007}
=======

The demographic and clinical characteristics are shown in Table [1](#tca12943-tbl-0001){ref-type="table"}. The median follow‐up duration was 32 (range: 1--120) months. In terms of treatment, 31.4% cases underwent sublobar resection (86.0% wedge resection and 14.0% segmentectomy) and 68.6% underwent lobectomy. In patients treated with surgery, 22.3% (122/548) received radiation therapy (8 patients received radiation prior to surgery, 1 received intra‐operative radiation, and 113 patients received radiation after surgery). Gender, race, tumor location, histology, and radiotherapy did not differ significantly between the surgical type groups. Sublobar resection was performed more frequently on older patients and those with smaller tumors (*P* \< 0.05). However, the aforementioned covariates were well balanced after PSM analysis.

###### 

The demographics and clinical characteristics of SCLC patients

  Variable                Category      No. (%) of patients      *P*      \*Adjusted   
  -------------------- --------------- --------------------- ------------ ------------ -------
  Age at diagnosis         Median               66                71      \< 0.001      0.057
                            Range             40--90            39--89                 
  Age group (year)          ≤ 65            175 (46.6)        59 (34.3)   0.002         0.334
                           66--75           129 (34.3)        58 (33.7)                
                            ≥ 76             72 (19.1)        55 (32.0)                
  Gender                    Male            168 (44.7)        81 (47.1)   0.644         0.516
                           Female           208 (55.3)        91 (52.9)                
  Race                      White           339 (90.1)        162 (94.0)  0.169         0.505
                            Black            22 (5.9)          8 (4.8)                 
                            Other            15 (4.0)          2 (1.2)                 
  Primary site          Main bronchus         2 (0.6)          1 (0.6)    0.367         0.151
                         Upper lobe         232 (61.5)        114 (66.1)               
                         Middle lobe         29 (7.7)          5 (3.0)                 
                         Lower lobe         108 (28.7)        50 (29.1)                
                         Overlapping          1 (0.3)          1 (0.6)                 
                          Lung, NOS           4 (1.2)          1 (0.6)                 
  Histology                  NOS            270 (71.8)        130 (75.6)  0.517         0.726
                             Oat             15 (4.0)          8 (4.7)                 
                          Fusiform            2 (0.5)          0 (0.0)                 
                        Intermediate         15 (4.0)          3 (1.7)                 
                          Combined           74 (19.7)        31 (18.0)                
  Tumor size (cm)           ≤ 3.0           293 (77.9)        157 (90.7)  0.001         0.183
                          3.1--5.0           83 (22.1)         15 (9.3)                
  Radiotherapy               No             294 (78.2)        120 (69.8)  0.101         0.323
                             Yes             75 (19.9)        47 (27.3)                
                           Unknown            7 (1.9)          5 (2.9)                 
  LCSS status              Alive†           243 (64.6)        83 (48.3)   \< 0.001      0.013
                            Died‡           133 (35.4)        89 (51.7)                
  Follow‐up (months)       Median               32                23      \< 0.001      0.003
                            Range             1--120            1--120                 

\**P* value adjusted by propensity score matching. †Alive, alive or died of another cause; ‡Died, death attributable to lung cancer. LCSS, lung cancer‐specific survival; NOS, not otherwise specified; SCLC, small cell lung cancer.

The three‐year OS rates of patients treated by lobectomy or sublobar resection were 60% and 38%, respectively (*P* \< 0.001) (Fig [1](#tca12943-fig-0001){ref-type="fig"}a); the corresponding three‐year LCSS rates of these two groups were 61% and 40%, respectively (*P* \< 0.001) (Fig [1](#tca12943-fig-0001){ref-type="fig"}b). PSM analysis generated similar results (Fig [1](#tca12943-fig-0001){ref-type="fig"}c,d). The three‐year OS rates of T1 disease lobectomy and sublobar cohorts were 61% and 39%, respectively (*P* \< 0.001) (Fig [2](#tca12943-fig-0002){ref-type="fig"}a); the corresponding three‐year LCSS rates were 68% and 47%, respectively (*P* \< 0.001, Fig [2](#tca12943-fig-0002){ref-type="fig"}b). The three‐year OS rates of T2 SCLC lobectomy and sublobar cohorts were 56% and 27%, respectively (*P* = 0.008) (Fig [2](#tca12943-fig-0002){ref-type="fig"}c); the corresponding three‐year LCSS rates were 57% and 36%, respectively (*P* = 0.003) (Fig [2](#tca12943-fig-0002){ref-type="fig"}d).

![Kaplan--Meier curves of (**a**) overall survival (OS) and (**b**) lung cancer‐specific survival (LCSS) and propensity‐matched analysis of (**c**) OS and (**d**) LCSS. (![](TCA-10-593-g004.jpg "image")) Lobectomy and (![](TCA-10-593-g005.jpg "image")) Sublobectomy. CI, confidence interval; HR, hazard ratio; SCLC, small cell lung cancer.](TCA-10-593-g001){#tca12943-fig-0001}

![Kaplan--Meier curves of (**a**) overall survival (OS) and (**b**) lung cancer‐specific survival (LCSS) and in T1 small cell lung cancer (SCLC). (**c**) OS and (**d**) LCSS in T2 SCLC. (![](TCA-10-593-g006.jpg "image")) Lobectomy and (![](TCA-10-593-g007.jpg "image")) Sublobectomy. CI, confidence interval; HR, hazard ratio.](TCA-10-593-g002){#tca12943-fig-0002}

In the sublobar cohort, there was no difference in baseline characteristics between segmentectomy and wedge resection (Table [2](#tca12943-tbl-0002){ref-type="table"}). The trend in survival benefit favored segmentectomy over to wedge resection, but there was no statistical difference between the two methods. The three‐year OS rate of the segmentectomy and wedge cohorts were 52% and 35%, respectively (*P* = 0.071) (Fig [3](#tca12943-fig-0003){ref-type="fig"}a); the corresponding three‐year LCSS rates were 54% and 45%, respectively (*P* = 0.482) (Fig [3](#tca12943-fig-0003){ref-type="fig"}b). PSM analysis revealed that segmentectomy conferred a superior survival advantage over wedge resection (3‐year OS: 54% vs. 18%; *P* = 0.044) (Fig [3](#tca12943-fig-0003){ref-type="fig"}c,d). In addition, analyses of survival of patients who died within one month of diagnosis (Fig [S2](#tca12943-supitem-0001){ref-type="supplementary-material"}) and of radiotherapy (Fig [S3](#tca12943-supitem-0001){ref-type="supplementary-material"}) and separate analyses of patient data from the SEER database between 2009 and 2013 (Fig [S4](#tca12943-supitem-0001){ref-type="supplementary-material"}) were performed, which generated consistent outcomes.

###### 

The demographics and clinical characteristics of patients in the sublobar resection cohort

  Variable                Category     No. (%) of Patients   *P*         \*Adjusted   
  -------------------- --------------- --------------------- ----------- ------------ -------
  Age at diagnosis         Median      71                    70          0.326        0.569
                            Range      39--89                52--83                   
  Age group                  ≤65       51 (34.4)             8 (33.3)    0.316        0.623
                           66--75      47 (31.8)             11 (45.8)                
                             ≥76       50 (33.8)             5 (20.8)                 
  Gender                    Male       70 (47.3)             11 (45.8)   0.894        0.770
                           Female      78 (52.7)             13 (54.2)                
  Race                      White      140 (94.4)            22 (91.6)   0.333        0.364
                            Black      7 (4.9)               1 (4.2)                  
                            Other      1 (0.7)               1 (4.2)                  
  Primary site          Main bronchus  1 (0.7)               0 (0.0)     0.844        0.494
                         Upper lobe    99 (66.7)             15 (62.5)                
                         Middle lobe   5 (3.5)               0 (0.0)                  
                         Lower lobe    41 (27.7)             9 (37.5)                 
                         Overlapping   1 (0.7)               0 (0.0)                  
                          Lung, NOS    1 (0.7)               0 (0.0)                  
  Histology                  NOS       116 (78.4)            14 (58.3)   0.058        0.487
                             Oat       7 (4.7)               1 (4.2)                  
                          Fusiform     0 (0.0)               0 (0.0)                  
                        Intermediate   3 (2.0)               0 (0.0)                  
                          Combined     22 (14.9)             9 (37.5)                 
  Tumor size (cm)           ≤ 3.0      137 (92.6)            19 (79.2)   0.052        0.998
                          3.1--5.0     11 (7.4)              5 (20.8)                 
  Radiotherapy               No        103 (69.6)            17 (70.8)   0.899        0.834
                             Yes       41 (27.7)             6 (25.0)                 
                           Unknown     4 (2.7)               1 (4.2)                  
  LCSS status              Alive†      71 (48.0)             12 (50.0)   0.854        1.000
                            Died‡      77 (52.0)             12 (50.0)                
  Follow‐up (months)       Median      23                    31          0.166        0.829
                            Range      1--120                1--120                   

\**P* value adjusted by propensity score matching. †Alive, alive or died of another cause; ‡Died, death attributable to lung cancer. LCSS, lung cancer‐specific survival; NOS, not otherwise specified; SCLC, small cell lung cancer.

![Kaplan--Meier curves of (**a**) overall survival (OS) and (**b**) lung cancer‐specific survival (LCSS) and and propensity‐matched analysis of (**c**) OS and (**d**) LCSS in the sublobar cohort. (![](TCA-10-593-g008.jpg "image")) Lobectomy and (![](TCA-10-593-g009.jpg "image")) Sublobectomy. CI, confidence interval; HR, hazard ratio; SCLC, small cell lung cancer.](TCA-10-593-g003){#tca12943-fig-0003}

Based on univariate analysis, we noted that age, gender, and surgery type were significant prognostic factors (*P* \< 0.05). Based on multivariate analysis, the prognosis was better for patients who underwent lobectomy compared to those who underwent sublobar resection (OS: HR 0.54, 95% CI 0.42--0.68, *P* \< 0.001; LCSS: HR 0.57, 95% CI 0.43--0.74, *P* \< 0.001). In the sublobar cohort, there was a clear trend of survival benefit in patients who underwent segmentectomy compared to those who underwent wedge resection, but this difference was not statistically significant. The results of univariate and multivariate analyses are listed in Tables [3](#tca12943-tbl-0003){ref-type="table"} and [4](#tca12943-tbl-0004){ref-type="table"}.

###### 

Univariate and multivariate analysis of OS in the whole cohort

  Covariate                          Univariate       Multivariate                      
  ----------------------------- -------------------- -------------- ------------------- ----------
  Age at diagnosis               1.03 (1.02--1.05)      \< 0.001     1.06 (1.03--1.09)   \< 0.001
  Gender, (ref = male)                                                                  
  Female                         0.72 (0.57--0.90)       0.004       0.68 (0.54--0.85)    0.001
  Race, (ref = white)                                                                   
  Black                          0.63 (0.35--1.12)       0.115              ---            ---
  Other                          0.69 (0.36--1.36)       0.293              ---            ---
  Primary site, (ref = upper)                                                           
  Middle                         0.87 (0.52--1.42)       0.572              ---            ---
  Lower                          1.06 (0.83--1.37)       0.646              ---            ---
  Overlapping                    2.58 (0.64--10.39)      0.184              ---            ---
  Histology, (ref = Combined)                                                           
  Oat                            1.29 (0.72--2.31)       0.389              ---            ---
  Fusiform                              ---               ---               ---            ---
  Intermediate                   1.42 (0.75--2.67)       0.281              ---            ---
  NOS                            1.18 (0.87--1.62)       0.290              ---            ---
  Tumor size, (ref = ≤ 3.0)                                                             
  3.1--5.0                       1.05 (0.78--1.39)       0.768       1.16 (0.86--1.55)    0.335
  Radiotherapy, (ref = No)                                                              
  Yes                            0.86 (0.65--1.13)       0.279       1.04 (0.77--1.41)    0.820
  Surgery type, (ref = Wedge)                                                           
  Segmentectomy                  0.61 (0.34--1.08)       0.091       0.58 (0.32--1.04)    0.069
  Lobectomy                      0.50 (0.39--0.64)      \< 0.001     0.60 (0.45--0.79)   \< 0.001

CI, confidence interval; HR, hazard ratio; NOS, not otherwise specified; OS, overall survival.

###### 

Univariate and multivariate analysis of LCSS in the whole cohort

  Covariate                          Univariate      Multivariate                       
  ----------------------------- -------------------- -------------- ------------------- ----------
  Age at diagnosis               1.04 (1.02--1.05)   \< 0.001        1.05 (1.01--1.08)  0.008
  Gender, (ref = male)                                                                  
  Female                         0.68 (0.52--0.88)   0.004           0.63 (0.49--0.83)  0.001
  Race, (ref = white)                                                                   
  Black                          0.65 (0.34--1.27)   0.211                  ---         ---
  Other                          0.90 (0.44--1.83)   0.779                  ---         ---
  Primary site, (ref = upper)                                                           
  Middle                         0.82 (0.46--1.48)   0.518                  ---         ---
  Lower                          1.07 (0.79--1.44)   0.648                  ---         ---
  Overlapping                    3.30 (0.82--13.34)  0.094                  ---         ---
  Histology, (ref = Combined)                                                           
  Oat                            1.22 (0.60--2.46)   0.579                  ---         ---
  Fusiform                              ---          ---                    ---         ---
  Intermediate                   1.48 (0.71--3.09)   0.291                  ---         ---
  NOS                            1.19 (0.83--1.71)   0.344                  ---         ---
  Tumor size, (ref = ≤ 3.0)                                                             
  3.1--5.0                       1.29 (0.94--1.78)   0.110           1.45 (1.05--1.99)  0.024
  Radiotherapy, (ref = No)                                                              
  Yes                            0.98 (0.72--1.34)   0.911           1.12 (0.83--1.64)  0.377
  Surgery type, (ref = Wedge)                                                           
  Segmentectomy                  0.81 (0.44--1.48)   0.485           0.79 (0.43--1.48)  0.463
  Lobectomy                      0.55 (0.41--0.73)   \< 0.001        0.66 (0.47--0.92)  \< 0.001

CI, confidence interval; HR, hazard ratio; LCSS, lung cancer‐specific survival; NOS, not otherwise specified.

Discussion {#tca12943-sec-0008}
==========

As CT screening for lung cancer becomes more commonplace, the frequency of detecting smaller lung cancers will likely increase. SCLC is a rapidly progressive malignancy with a median survival of 17 months and five‐year OS of 10%.[14](#tca12943-bib-0014){ref-type="ref"}, [15](#tca12943-bib-0015){ref-type="ref"} The American Cancer Society estimates that even in stage I SCLC, five‐year survival is only 31%.[16](#tca12943-bib-0016){ref-type="ref"} Surgery is an accepted part of multimodality treatment for early‐stage disease. Few studies have discussed whether sublobar re section can achieve oncologic results equivalent to those of lobectomy in patients with stage T1‐2N0M0 SCLC. Evidence is needed to guide clinical decision‐making that balances both surgical risk and therapeutic efficacy in this patient population.

Early studies did not identify a significant benefit of surgical resection alone for patients with limited‐stage SCLC.[4](#tca12943-bib-0004){ref-type="ref"}, [17](#tca12943-bib-0017){ref-type="ref"} A retrospective study published in the 1970s reported poor outcomes for patients with resected SCLC.[18](#tca12943-bib-0018){ref-type="ref"} Most of the recent data regarding surgery in early‐stage SCLC patients is derived from observational studies of large data registries, which shows that beneficial outcomes have been achieved with surgical resection.[19](#tca12943-bib-0019){ref-type="ref"}, [20](#tca12943-bib-0020){ref-type="ref"}, [21](#tca12943-bib-0021){ref-type="ref"}, [22](#tca12943-bib-0022){ref-type="ref"}, [23](#tca12943-bib-0023){ref-type="ref"} The American College of Chest Physicians and the American Society of Clinical Oncology also recommend surgery for stage I SCLC patients, followed by adjuvant chemotherapy.[24](#tca12943-bib-0024){ref-type="ref"}, [25](#tca12943-bib-0025){ref-type="ref"} If resection is performed, the current NCCN guidelines recommend lobectomy. However, considering the potential advantages of preserving pulmonary function and the greater application of minimally invasive surgical techniques, many patients with early‐stage SCLC undergo sublobar resection. In this analysis, 31% of patients underwent sublobar resection, whereas a prior study reported that 33% of patients with stage T1‐2N0M0 SCLC underwent sublobar resection.[26](#tca12943-bib-0026){ref-type="ref"} Based on traditional multivariable and PSM analyses, as well as the results of sensitive analysis in this study, we found an association between sublobar resection and poor survival. Taken together, for T1‐2N0M0 SCLC patients for whom surgical resection is appropriate, lobectomy should be the first choice.

Because of advances in imaging studies and surgical techniques, sublobar resection is a reasonable approach for patients with early, small lung cancers, as indicated by a previous study.[27](#tca12943-bib-0027){ref-type="ref"} In this study, sublobar resection failed to demonstrate any efficacy, even for T1 tumors (≤ 3 cm). Similarly, lobectomy provides optimal local control and leads to superior survival.[28](#tca12943-bib-0028){ref-type="ref"} Therefore, lobectomy remains the standard of care for patients with T1 SCLC. For T2 disease, our results showed a higher risk of mortality after sublobar resection. OS and LCSS were statistically significantly different between the two treatment strategies. In the sublobar cohort, there was no significant difference in OS and LCSS for patients who underwent either segmentectomy or wedge resection. After PSM analysis, no differences in LCSS were noted for patients who underwent either segmentectomy or wedge resection (*P* = 0.168), but there was a significant difference in the OS rates (*P* = 0.040). Although no significant differences in OS or LCSS were observed for segmentectomy, observed trends in the PSM cohort suggest improved outcomes with segmentectomy. Given that only 24 patients were matched in each group, meaningful differences may become apparent if larger patient cohorts are compared. Segmentectomy may achieve better local control than wedge resection and is thus associated with OS benefit. These findings imply that if lobectomy cannot be performed, segmentectomy would likely provide a better prognosis than wedge resection.

The current study has some limitations. First, this was a retrospective study and patients treated with sublobar resection may be highly selected. Second, SEER does not provide data of several important factors, including pulmonary function testing, comorbidities, margin status, and the length of hospital stay. Third, clinical staging data was not available, which limited our ability to assess upstaging by LN examination or to perform "intent to treat" analysis. Unfortunately, chemotherapy data for SCLC are unavailable from this database, thus limiting this study\'s ability to describe treatment patterns in SCLC; similarly, responses to treatment and recurrence rates cannot be ascertained from the SEER database. The study strengths include large patient numbers, which are only achievable by querying large multi‐institution databases. PSM analysis further strengthens the power of our results.

In conclusion, in this study, sublobar resection was used for nearly one‐third of patients with pathological stage T1‐2N0M0 SCLC. Lobectomy yielded better survival. For patients unsuitable for lobectomy, segmentectomy seems to provide a better prognosis than wedge resection.
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**Figure S1.** The inclusion and exclusion process of the included cohort.
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Click here for additional data file.

###### 

**Figure S2.** Kaplan--Meier curves for (**a**) overall survival (OS) and (**b**) lung cancer‐specific survival (LCSS) in the study cohort (*n* = 548) and 17 patients who died within one month of diagnosis.
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Click here for additional data file.

###### 

**Figure S3.** Sensitive analysis of radiotherapy. Kaplan--Meier curves of (**a**) overall survival (OS) and (**b**) lung cancer‐specific survival (LCSS) in the radiation cohort, and (c) OS and (d) LCSS in the cohort not administered radiation.

###### 

Click here for additional data file.

###### 

**Figure S4.** Separate analysis of patient data from the Surveillance, Epidemiologic, and End Results (SEER) database between 2009 and 2013. Kaplan--Meier curves for (**a**) overall survival (OS) and (**b**) lung cancer‐specific survival (LCSS).

###### 

Click here for additional data file.
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